| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10970548 | Vaccine | 2007 | 8 Pages |
Abstract
Adolescent revaccination would be beneficial. Using C-MCV would be the most cost-effective option, while using MCV-4 would be more effective but would also require more investment.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Philippe De Wals, Laurent Coudeville, Pierre Trottier, Catherine Chevat, Lonny J. Erickson, Van Hung Nguyen,